

A. For Equity Issues

Name of the issue:

Metropolis Healthcare Ltd.

Last Updated: October, 2022

1 Type of issue (IPO/ FPO)	IPO
2 Issue size (Rs crore)	1,204.28
3 Grade of issue alongwith name of the rating agency	NA
4 Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.	3.68

5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)

(i) allotment in the issue	20.44%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2019)	21.71%
(iii) at the end of 1st FY (March 31, 2020)	22.24%
(iv) at the end of 2nd FY (March 31, 2021)	42.97%
(v) at the end of 3rd FY (March 31, 2022)	38.11%

6 Financials of the issuer*(Rs. in crores)*

Parameters	1st FY (March 31,2020)	2nd FY (March 31, 2021)	3rd FY (March 31, 2022)
Income from operations	856	998	1117
Net Profit for the period	128	183	192
Paid-up equity share capital	10	10	10
Reserves excluding revaluation reserves	513	696	814

7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)

(i) at the end of 1st FY	Frequently Traded
(ii) at the end of 2nd FY	Frequently Traded
(iii) at the end of 3rd FY	Frequently Traded

8 Change, if any, in directors of issuer from the disclosures in the offer document

	Name of Director	Appointed / Resigned
(i) at the end of 1st FY	NA	NA
(ii) at the end of 2nd FY	NA	NA
(iii) at the end of 3rd FY	NA	NA

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	NA
(ii) Actual implementation	NA
(iii) Reasons for delay in implementation, if any	NA

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document	NA
(ii) Actual utilization	NA
(iii) Reasons for deviation, if any	NA

11 **Comments of monitoring agency, if applicable**

(a) Comments on use of funds NA
 (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document NA
 (c) Any other reservations expressed by the monitoring agency about the end use of funds NA

(To be submitted till the time the issue proceeds have been fully utilised)

12 **Price- related data**

Issue price (Rs): 880
 Designated Stock Exchange BSE
 Listing Date 15-04-2019

Price parameters	At close of listing day	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue March 31, 2020			As at the end of 2nd FY after the listing of the issue March 31, 2021			As at the end of 3rd FY after the listing of the issue March 31, 2022		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price	959.55	912.85	1,043.65	1,286.25	2,110.00	904.85	2,241.05	2,344.95	1,150.00	2036.70	3579	1805.4
BSE Sensex	38905.84	37,318.53	38,896.71	29,468.49	42,273.87	25,638.90	49,509.15	52,516.76	27,500.79	58568.51	62245.43	47204.5
S&P BSE Healthcare	14505.67	13,452.29	13,012.26	12,148.57	14,663.74	10,947.99	21,328.21	22,464.34	11,878.39	24303.83	26979.05	21236.14

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

13 **Basis for Issue Price and Comparison with Peer Group & Industry Average** (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1st FY March 31, 2020	At the end of 2nd FY March 31, 2021	At the end of 3rd FY March 31, 2022
EPS	Consolidated (Basic)	20.61	25.36	35.97	41.87
	Peer Group:				
	Dr. Lal Pathlabs Limited	20.85	27.42	35.33	41.70
	Industry Avg:	20.85	27.42	35.33	41.70
P/E	Issuer:	42.70	50.72	62.30	48.64
	Peer Group:				
	Dr. Lal Pathlabs Limited	50.57	51.11	76.63	62.52
	Industry Avg:	50.57	51.11	76.63	62.52
RoNW%	Issuer:	24.66	24.37	25.95	24.37
	Peer Group:				
	Dr. Lal Pathlabs Limited	21.61	22.13	23.17	23.23
	Industry Avg:	21.61	22.13	23.17	23.23
NAV per share based on balance sheet	Issuer:	83.58	103.72	138.23	102.30
	Peer Group:				
	Dr. Lal Pathlabs Limited	96.93	123.92	153.10	18.09
	Industry Avg:	96.93	123.92	153.10	18.09

14 **Any other material information**

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com